title: Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease.
abstract: BACKGROUND
  Previous studies have demonstrated the safety and efficacy of using Paricalcitol for the treatment of secondary hyperparathyroidism (SHPT) in patients on dialysis. The aim of the current meta-analysis was to assess the safety and efficacy of Paricalcitol for the management of SHPT in patients with chronic kidney disease (CKD) not yet on dialysis. A secondary aim was to determine if sufficient data was available to assess the effect of Paricalcitol for the management of proteinuria.
  
  
  METHODS
  A meta-analysis was conducted using the Cochrane Collaboration's RevMan 4.2 software.
  
  
  RESULTS
  Paricalcitol is effective in lowering PTH in patients with CKD not yet on dialysis and is also effective in lowering proteinuria in diabetic CKD patients. However, we uncovered a safety signal identifying an elevated calcium phosphate product and a trend towards the development of hypercalcemia. A phosphate elevation was not demonstrated because the target used in the clinical studies was a P > 5.5 mg/dl, a value appropriate for dialysis patients and not CKD patients.
  
  
  CONCLUSIONS
  Although Paricalcitol is effective in lowering PTH, we advise caution in the use of any active Vitamin D analogues in patients with CKD because of the potential risk of exacerbating vascular calcification.
authors.affiliation: The Department of Nephrology, The Third People's Hospital of Chengdu, The Chongqing Medical University, Chengdu 610031, China.
authors.forename: Tianzhao
authors.initials: T
authors.lastname: Han
authors.forename: Gong
authors.initials: G
authors.lastname: Rong
authors.forename: Dayong
authors.initials: D
authors.lastname: Quan
authors.forename: Ying
authors.initials: Y
authors.lastname: Shu
authors.forename: Zhu
authors.initials: Z
authors.lastname: Liang
authors.forename: Ninglan
authors.initials: N
authors.lastname: She
authors.forename: Manli
authors.initials: M
authors.lastname: Liu
authors.forename: Bing
authors.initials: B
authors.lastname: Yang
authors.forename: Gong
authors.initials: G
authors.lastname: Cheng
authors.forename: Yongman
authors.initials: Y
authors.lastname: Lv
authors.forename: Leonard
authors.initials: L
authors.lastname: Stern
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004872:Ergocalciferols / Q000009:adverse effects / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D054559:Hyperphosphatemia / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D011507:Proteinuria / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D016896:Treatment Outcome; D014807:Vitamin D / Q000031:analogs & derivatives
chemical_list: D050071:Bone Density Conservation Agents; D004872:Ergocalciferols; D014807:Vitamin D; C084656:paricalcitol